Lung Cancer Trial, Completed (NCT01662635)

Lung Cancer Trial, Completed NCT01662635 Sponsor: Instituto Nacional de Cancerologia de Mexico Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT01662635 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 230 people, with 200 completing the study and 30 not completing it. The trial was looking at three different laboratory testing methods used to detect a genetic change called ALK — a particular alteration in a gene that can be found in some cancer tumours. The three methods tested were FISH (a technique that uses fluorescent tags to spot gene changes), IHC (a staining method that detects certain proteins in tissue), and RT-qPCR (a method that measures genetic material). The goal was to compare how these three tests performed against each other on the same samples. The reported data shows that all 200 completed samples were tested using the FISH method. From those 200 samples, 63 were also tested using IHC, and 48 were tested using RT-qPCR. According to the results reported on ClinicalTrials.gov, the FISH test returned 18 positive results and 182 negative results. The IHC test, run on the smaller group of 63 samples, returned 15 positive results and 48 negative results. The RT-qPCR test, run on 48 samples, returned 5 positive results and 43 negative results. No further breakdown or additional outcome measures were reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You must have tissue samples available that can be used for biomarker testing (biological marker studies).

Who may not be able to join:

People whose disease has gotten worse or spread (progressed) may not be able to join.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:

Trial: NCT01662635

Sponsor: Instituto Nacional de Cancerologia de Mexico

Phase: Not Applicable

Status: Completed

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT01662635

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You must have tissue samples available that can be used for biomarker testing (biological marker studies).

Who may not be able to join:

People whose disease has gotten worse or spread (progressed) may not be able to join.

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Completed

Phase

Not Applicable

Sponsor

Instituto Nacional de Cancerologia de Mexico

Registry

ClinicalTrials.gov

Start date

1 February 2011

Est. completion

1 September 2014

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

FISH, IHC, RT-qPCR Comparison

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov